Chris Franzese and Marty Coyne discuss the vast potential that voice-activated technologies, such as Amazon’s Alexa, have in the healthcare market. Running through the challenges posed by data security and human factors, they go on to explain how the rewards voice-activation offers are well worth the effort, spanning the drug delivery experience.
Charlotte Harvey examines the opportunities and practicalities of using energy harvesting technologies in drug delivery devices. With a specific focus on enabling connectivity functionality, Ms Harvey runs through the various aspects of energy harvesting and offers insight on whether it is the right choice for a new device development.
Helen Simons and Stephanie Ward describe how the new EU Medical Devices Regulation will impact on “grandfathered” devices that were approved under old regulation and are currently on the market, but do not necessarily comply with current/updated regulatory standards, and explain the potential implications for device manufacturers.
Nozer Mehta, James P Gilligan and William Stern summarise the different technologies that have been in development for oral delivery of peptides through the gastro-intestinal mucosal surfaces via the transcellular or the paracellular pathways and describe the results of several long-term clinical studies on the oral delivery of salmon calcitonin.
Neil Fletcher provides a spring manufacturer’s perspective of how springs can be used in medical devices, and how a lengthy and extensive device development process affects normal custom and practice in our industry. The report focuses on spring technology and highlights some of the challenges that spring manufacturers face daily.